Predictive Biomarker for Metformin Response in Endometrial Cancer

Technology #18-0050

An indicator of therapeutic response to metformin in endometrial cancer (EC) patients has been identified. In a subset of obese patients, preoperative metformin therapy has been linked to decreased tumor proliferation. Differential proteomic analysis of tumor cells collected from EC patient tissue revealed discrepancies in molecular signaling pathways between metformin responder and non-responder patients. UNC inventors utilized this data to discover a biomarker that can be used to predict the preoperative therapeutic response to metformin treatment in endometrial cancer patients.

Advantages:
- Can predict success of preoperative metformin therapy

Related Publications:

- Increased efficacy of metformin corresponds to differential metabolic effects in the ovarian tumors from obese versus lean mice.
Han, J., et al.; Oncotarget. 2017 Sep 8, 8(67): 110965-110982

Inventors

Victoria Bae-Jump

For additional information, contact

Kyle Bartholomew
Commercialization Manager
kyle.bartholomew@unc.edu
919.962.5921